BIIB Biogen Inc.

302.6
-0.26  -0%
Previous Close 302.86
Open 303.04
Price To Book 3.94
Market Cap 49,380,533,264
Shares 163,187,486
Volume 945,550
Short Ratio
Av. Daily Volume 1,811,230
Stock charts supplied by TradingView

NewsSee all news

  1. Vir Biotechnology and Biogen Execute Agreement to Manufacture SARS-CoV-2 Antibodies for Potential COVID-19 Treatment

    SAN FRANCISCO, May 29, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that is has finalized a process development and manufacturing agreement with Biogen Inc. (NASDAQ:BIIB) based on the

  2. Biogen and MIT Launch New Virtual Learning Lab for High School Students Historically Underrepresented in Science

    The online learning program combines lab simulations and mentoring experiences focused on biotechnology and neurological diseases, such as Parkinson's disease, Alzheimer's disease and multiple sclerosisFour hundred

  3. New SPINRAZA® (nusinersen) Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of Spinal Muscular Atrophy (SMA) Patients

    Treatment with SPINRAZA improved or stabilized motor function across patient populations, including young adultsThe longer-term safety profile of SPINRAZA was consistent among a broad spectrum of ages and SMA typesNew

  4. Samsung Bioepis Announces 24-week Interim Results from a Phase 3 Trial of SB11, Proposed Ranibizumab Biosimilar

    In a Phase 3 study, SB11 demonstrated equivalent efficacy in terms of change in best corrected visual activity (BCVA) at Week 8 and central subfield thickness (CST) at Week 4 to reference ranibizumab LUCENTIS®i in

  5. Vir Biotechnology Provides Corporate Update and Reports First Quarter 2020 Financial Results

    SAN FRANCISCO, May 12, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today provided a corporate

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2/3 data due mid-2020.
BIIB112
X-linked Retinitis Pigmentosa
Phase 3 data due towards the end of 2020.
BIIB111
Choroideremia
Phase 2 data due 2H 2020.
BIIB054
Parkinson's disease
Phase 2 data due 1H 2020.
Natalizumab - OPUS
Epilepsy
Phase 3 data due by end of 2021.
BIIB093
Large hemispheric infarction
Phase 3 ready to be initiated. Acquired from Remedy Pharmaceuticals May 15, 2017.
CIRARA (intravenous glyburide)
Ischemic stroke
Phase 2 trial did not meet primary endpoint - December 13, 2019.
BIIB092 - Anti Tau
Progressive supranuclear palsy (PSP)
Phase 3 trial discontinued due to unfavorable risk-benefit ratio.
Elenbecestat (E2609) - (MissionAD2)
Alzheimer’s disease
BLA filing to be completed 3Q 2020.
Aducanumab
Alzheimer’s disease
Phase 3 trial to be initiated later in 2019.
BIIB074 (Nav1.7 inhibitor)
Trigeminal Neuralgia
Phase 3 trial discontinued due to unfavorable risk-benefit ratio.
Elenbecestat (E2609) - (MissionAD1)
Alzheimer’s disease
Phase 2b data due 2H 2020.
Opicinumab (AFFINITY)
Multiple sclerosis (MS)
Phase 3 trial discontinued due to futility - unlikely to meet primary endpoint upon completion - March 21, 2019.
Aducanumab (Aβ mAb) - ENGAGE
Alzheimer’s disease
Phase 2b data released February 8, 2018 - primary endpoint not met.
Natalizumab (α4-integrin inhibitor)
Acute ischemic stroke
Phase 2 data released September 2018 - primary endpoint not met.
Raxatrigine - BIIB074 (Nav1.7 inhibitor)
Painful Lumbosacral Radiculopathy (PLSR)
Phase 2 topline data showed no statistically significant treatment effect for primary and secondary endpoints - 1Q 2016.
Raxatrigine - BIIB074 (Nav1.7 inhibitor)
Erythromelagia
Phase 2 data met primary endpoint - December 3, 2019.
BIIB059 (anti-BDCA2)
Lupus
Phase 2b data released October 23, 2018 - primary endpoint not met.
Dapirolizumab pegol (anti-CD40L)
Lupus
Phase 3 initiation announced March 22. 2019.
BAN2401
Alzheimer’s disease
Phase 2b trial discontinued August 2019 due to safety concerns.
BG00011 (STX-100)
Idiopathic pulmonary fibrosis (IPF)
FDA Approval announced October 30, 2019.
Diroximel fumarate (BIIB098)
Multiple sclerosis (MS)
Phase 3 data due 2021.
IONIS-SOD1Rx / BIIB067
Amyotrophic lateral sclerosis (ALS)
Phase 3b trial initiation announced January 3, 2019.
Natalizumab - NOVA
Multiple sclerosis (MS)
Phase 2b data due 2H 2021.
BIIB104
Cognitive Impairment Associated With Schizophrenia (CIAS)
Phase 2 data due late-2020.
TMS-007
Acute ischemic stroke
Phase 2 data due 2021.
BIIB074 (Nav1.7 inhibitor)
Small Fibre Neuropathy
Phase 2/3 initiation announced September 18, 2019.
SPINRAZA - DEVOTE
Spinal muscular atrophy (SMA)
Phase 2/3 commencement of dosing announced April 2, 2020.
SPINRAZA (nusinersen) - high dose
Spinal muscular atrophy (SMA)

Latest News

  1. Vir Biotechnology and Biogen Execute Agreement to Manufacture SARS-CoV-2 Antibodies for Potential COVID-19 Treatment

    SAN FRANCISCO, May 29, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that is has finalized a process development and manufacturing agreement with Biogen Inc. (NASDAQ:BIIB) based on the

  2. Biogen and MIT Launch New Virtual Learning Lab for High School Students Historically Underrepresented in Science

    The online learning program combines lab simulations and mentoring experiences focused on biotechnology and neurological diseases, such as Parkinson's disease, Alzheimer's disease and multiple sclerosisFour hundred

  3. New SPINRAZA® (nusinersen) Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of Spinal Muscular Atrophy (SMA) Patients

    Treatment with SPINRAZA improved or stabilized motor function across patient populations, including young adultsThe longer-term safety profile of SPINRAZA was consistent among a broad spectrum of ages and SMA typesNew

  4. Samsung Bioepis Announces 24-week Interim Results from a Phase 3 Trial of SB11, Proposed Ranibizumab Biosimilar

    In a Phase 3 study, SB11 demonstrated equivalent efficacy in terms of change in best corrected visual activity (BCVA) at Week 8 and central subfield thickness (CST) at Week 4 to reference ranibizumab LUCENTIS®i in

  5. Vir Biotechnology Provides Corporate Update and Reports First Quarter 2020 Financial Results

    SAN FRANCISCO, May 12, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today provided a corporate

  6. Biogen Prices $3.0 Billion of Senior Unsecured Notes

    CAMBRIDGE, Mass., April 27, 2020 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced today the pricing of two series of senior unsecured notes for an aggregate principal amount of $3.0 billion. The notes will

  7. Biogen Releases 2019 Corporate Responsibility Report Demonstrating Continuous Progress Across Environmental, Social and Governance Metrics

    Continued to improve absolute environmental performance across energy, water and waste metrics while growing the business in 2019; has remained carbon neutral for six years in a rowAdvanced health equity and diversity

  8. Biogen, Broad Institute of MIT and Harvard, Partners HealthCare Launch Consortium to Build and Share a COVID-19 Biobank

    Biogen employees, family members, and other close contacts can contribute blood samples and medical data to aid efforts to rapidly understand and overcome COVID-19 Biobank to provide scientists with access to a large

  9. Samsung Biologics and Vir Biotechnology Enter into Agreement for Large Scale Manufacture of SARS-COV-2 Antibodies for Potential COVID-19 Treatment

    SONGDO, South Korea and SAN FRANCISCO, April 9, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and Vir Biotechnology, Inc. (NASDAQ:VIR) today announced a manufacturing agreement under which Samsung Biologics will

  10. Sangamo Announces Closing of Biogen Collaboration Agreement

    - Sangamo has received $225 million in stock proceeds; will receive additional $125 million upfront license fee by May 8, 2020 Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced the

  11. Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study

    DEVOTE will evaluate the safety and potential for even greater efficacy of a higher dose of SPINRAZA in the treatment of spinal muscular atrophy (SMA)Well-established safety profile and proven efficacy of SPINRAZA in a

  12. Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results

    SAN FRANCISCO, March 26, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today provided a corporate

  13. Vir Biotechnology Proceeding with Two Clinical Development Candidates for COVID-19

    - Multiple antibodies identified that neutralize SARS-CoV-2- Phase 1/2 clinical testing planned for this summer SAN FRANCISCO, March 25, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today

  14. S&P 500 buybacks up 3.2% in Q4 2019; Full Year 2019 down 9.6% from record 2018, as companies brace for a more volatile 2020

    NEW YORK, March 24, 2020 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") announced today that preliminary Q4 2019 S&P 500® stock buybacks, or share repurchases, were $181.6 billion – a 3.2% increase

  15. Biogen Foundation Commits $10 Million to Support COVID-19 Relief Efforts in the U.S. and Around the World

    Most of the funds will be directed to support the global response and the immediate needs of communities hardest hit by COVID-19 CAMBRIDGE, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today

  16. Vir Biotechnology Announces Intent to Collaborate with Biogen on Manufacturing of Antibodies to Potentially Treat COVID-19

    SAN FRANCISCO, March 12, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that it has signed a letter of intent with Biogen Inc. (NASDAQ:BIIB) for the development and clinical manufacturing

  17. Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer's, Parkinson's, Neuromuscular, and Other Neurological Diseases

    Broad collaboration for gene regulation therapies in neurology, initially focused on development of ST-501 for tauopathies including Alzheimer's disease, ST-502 for synucleinopathies including Parkinson's disease, and

  18. Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer's Disease and Parkinson's Disease from Pfizer Inc.

    PF-05251749 is a CNS-penetrant regulator of circadian rhythm with potential to address behavioral and neurological symptoms across various psychiatric and neurological diseases  Biogen to pay Pfizer $75 million upfront

  19. CAMP4 Announces Collaboration to Discover Novel Targets to Address Neurodegenerative and Neurological Diseases

    -- CAMP4 to receive $15 million upfront payment, and development and milestone payments of up to $96 million, plus future royalties, for each of the initial selected targets and up to $173 million, plus future

  20. Behind the Seizure® Program Further Expands Access to Genetic Testing for Children to Speed the Diagnosis of Genetic Epilepsy

    SAN FRANCISCO, Jan. 8, 2020 /PRNewswire/ -- Today BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Invitae Corporation (NYSE:NVTA) announced that Biogen (NASDAQ:BIIB), Encoded Therapeutics, Neurogene, Praxis Precision

  21. Catalyst Biosciences Announces Global License and Collaboration Agreement to Develop Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration

    SOUTH SAN FRANCISCO, Calif., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced it has entered into a global license and collaboration agreement with Biogen Inc. (NASDAQ:BIIB)

  22. Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy

    CAMBRIDGE, Mass., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Today, Biogen Inc. (NASDAQ:BIIB) announced topline results from the Phase 2 PASSPORT study of gosuranemab (BIIB092) for progressive supranuclear palsy (PSP). The

  23. Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE)

    The Phase 2 LILAC study met its primary endpoints, demonstrating statistically significant reduction of disease activity in patients with CLE and SLE who received BIIB059 compared to placeboPositive results support

  24. Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate)

    CAMBRIDGE, Mass., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced detailed results from the Phase 3 EVOLVE-MS-2 study demonstrating the improved patient-assessed gastrointestinal (GI)

  25. Biogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study for an Inherited Retinal Disorder

    CAMBRIDGE, Mass., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced today the enrollment of the last patient in the global Phase 3 STAR clinical study, which is evaluating the investigational gene

  26. Cognition Therapeutics to Give Webcast Presentation at Annual Piper Jaffray Healthcare Conference on December 3, 2019

    PITTSBURGH, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer's disease and other

  27. Alkermes Announces Receipt of $150 Million Milestone Payment from Biogen Related to FDA Approval of VUMERITY™

    DUBLIN, Nov. 12, 2019 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the receipt of a $150 million milestone payment from Biogen triggered by the recent U.S. Food and Drug Administration (FDA) approval of

  28. Samsung Bioepis Enters into Commercialization Agreement for Next-Generation Biosimilar Candidates

    Agreement with Biogen covers Samsung Bioepis' biosimilar candidates in pre-clinical and clinical development, which reference two widely-used biologic medicines in ophthalmology: ranibizumab and aflibercept Includes

  29. Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis

    Biogen to gain exclusive commercialization rights to two new ophthalmology biosimilars referencing Lucentis and Eylea in the U.S., Canada, Europe, Japan and AustraliaWill provide Biogen with commercialization rights for

  30. Biogen to Host Investor Webcasts from Clinical Trials on Alzheimer's Disease (CTAD) Congress on December 5, 2019

    CAMBRIDGE, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Biogen (NASDAQ:BIIB) today announced it will host live webcasts of its oral presentation and a Q&A session related to its Alzheimer's disease investigational

  31. Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis

    CAMBRIDGE, Mass. and DUBLIN, Ireland, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) and Alkermes plc (NASDAQ:ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY™

  32. Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis

    CAMBRIDGE, Mass. and DUBLIN, Ireland, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) and Alkermes plc (NASDAQ:ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY™

  33. Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis

    CAMBRIDGE, Mass. and DUBLIN, Ireland, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) and Alkermes plc (NASDAQ:ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY™

  34. Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis

    CAMBRIDGE, Mass. and DUBLIN, Ireland, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) and Alkermes plc (NASDAQ:ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY™

  35. Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis

    CAMBRIDGE, Mass. and DUBLIN, Oct. 30, 2019 /PRNewswire/ -- Biogen Inc. (NASDAQ:BIIB) and Alkermes plc (NASDAQ:ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY™ (diroximel

  36. Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis

    CAMBRIDGE, Mass. and DUBLIN, Oct. 30, 2019 /PRNewswire/ -- Biogen Inc. (NASDAQ:BIIB) and Alkermes plc (NASDAQ:ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY™ (diroximel

  37. Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis

    CAMBRIDGE, Mass. and DUBLIN, Oct. 30, 2019 /PRNewswire/ -- Biogen Inc. (NASDAQ:BIIB) and Alkermes plc (NASDAQ:ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY™ (diroximel

  38. Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis

    CAMBRIDGE, Mass. and DUBLIN, Oct. 30, 2019 /PRNewswire/ -- Biogen Inc. (NASDAQ:BIIB) and Alkermes plc (NASDAQ:ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY™ (diroximel

  39. Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Based on New Analysis of Larger Dataset from Phase 3 Studies

    TOKYO, Oct 23, 2019 - (JCN Newswire) - Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) has announced that, after consulting with the U.S.

  40. Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Based on New Analysis of Larger Dataset from Phase 3 Studies

    New analysis of larger dataset showed that aducanumab reduced clinical decline in patients with early Alzheimer's disease as measured by the pre-specified primary and secondary endpoints Based on discussions with the

  41. Biogen and Samsung Bioepis to Present Data for Infliximab and Adalimumab Biosimilars at United European Gastroenterology Week

    Data highlights real-world evidence confirming the safety and efficacy of anti-TNF biosimilars for patients with inflammatory bowel disease (IBD) CAMBRIDGE, Mass. and INCHEON, Korea, Oct. 21, 2019 (GLOBE NEWSWIRE) --

  42. NURTURE study shows pre-symptomatic Spinal Muscular Atrophy (SMA) infants treated with SPINRAZA™ (nusinersen injection) attained positive results

    Treatment with SPINRAZA™ resulted in survival of 100 percent of infants and none requiring permanent ventilation Recently published outcomes include motor milestones achieved in 100 percent of infants sitting without

  43. Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders

    Treatment with SPINRAZA resulted in survival of 100 percent of infants, with none requiring permanent ventilationMotor milestones achieved included 100 percent of participants sitting without support and 88 percent

  44. Biogen Announces Leadership Update

    Dr. Alfred Sandrock is named Executive Vice President, Research and Development and continues as Chief Medical Officer Dr. Alphonse Galdes appointed Executive Vice President, Pharmaceutical Operations and Technology

  45. Interferon Beta Treatments, Including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), Receive Positive CHMP Opinion for Use During Pregnancy and Breastfeeding

    Positive opinion is supported by data from more than 1,000 real-world pregnancy outcomes Data indicate no increased risk of major congenital anomalies after exposure to interferon beta before conception and/or during

  46. Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients

    DEVOTE trial to evaluate safety and even greater efficacy of a higher dose of SPINRAZA in the treatment of SMA; well-established safety profile supports exploration of potential benefitsLong-term data from the SHINE

  47. Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index

    CAMBRIDGE, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced that it has been ranked the #1 biotechnology company on the Dow Jones Sustainability World Index (DJSI World) for the

  48. Eisai And Biogen To Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease

    WOODCLIFF LAKE, N.J., Sept. 13, 2019 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel

  49. New Research Demonstrate Biogen's Continued Commitment to Improve Care of Patients with Multiple Sclerosis Across Treatment Spectrum

    Data highlight benefits of TYSABRI® (natalizumab) treatment in early multiple sclerosis for achieving NEDA (no evidence of disease activity) and improving disability and cognitionAn analysis of data from the TYSABRI

  50. New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA® (dimethyl fumarate) Over 10 Years

    TECFIDERA consistently maintained low levels of disease activity with no increased risk in adverse events over a decade of treatmentLatest interim data from Phase 3 EVOLVE-MS-1 trial show Biogen and Alkermes'